tetano
Editor, Senior Moderator
Ocul Immunol Inflamm
. 2023 Mar 8;1-7.
doi: 10.1080/09273948.2023.2182324. Online ahead of print.
Scleritis and Episcleritis following Coronavirus Disease (COVID-19) Vaccination
Srinivasan Sanjay[SUP] 1 [/SUP], Ashit Handa[SUP] 1 2 [/SUP], Ankush Kawali[SUP] 1 [/SUP], Rohit Shetty[SUP] 3 [/SUP], Sai Bhakti Mishra[SUP] 1 [/SUP], Padmamalini Mahendradas[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease (COVID-19) vaccines have been reported to have ocular side effects including scleritis and episcleritis.
Purpose: To report scleritis and episcleritis within a month following administration of COVID-19 vaccine.
Methods: Retrospective case series.
Results: 15 eyes of 12 consecutive patients with scleritis and episcleritis from March 2021 to September 2021 were included. The mean time of onset of symptoms in patients with scleritis was 15.7 days (range, 4-30) and for episcleritis it was 13.2 days (range 2-30). Patients received COVISHIELD™ (10 patients) and COVAXIN™ (2 patients). Five patients had denovo inflammation and seven had recurrent inflammation. Episcleritis patients were treated with topical steroids and systemic COX2 inhibitors while patients with scleritis were treated with topical steroids/oral steroids/antiviral medications depending on the aetiology.
Conclusion: Scleritis and episcleritis following COVID-19 vaccination are milder and do not require intensive immunosuppression except in rare cases.
Keywords: COVAXINTM; COVID-19 vaccines; COVISHIELDTM; episcleritis; scleritis; topical steroids.
. 2023 Mar 8;1-7.
doi: 10.1080/09273948.2023.2182324. Online ahead of print.
Scleritis and Episcleritis following Coronavirus Disease (COVID-19) Vaccination
Srinivasan Sanjay[SUP] 1 [/SUP], Ashit Handa[SUP] 1 2 [/SUP], Ankush Kawali[SUP] 1 [/SUP], Rohit Shetty[SUP] 3 [/SUP], Sai Bhakti Mishra[SUP] 1 [/SUP], Padmamalini Mahendradas[SUP] 1 [/SUP]
Affiliations
- PMID: 36884356
- DOI: 10.1080/09273948.2023.2182324
Abstract
Introduction: Coronavirus disease (COVID-19) vaccines have been reported to have ocular side effects including scleritis and episcleritis.
Purpose: To report scleritis and episcleritis within a month following administration of COVID-19 vaccine.
Methods: Retrospective case series.
Results: 15 eyes of 12 consecutive patients with scleritis and episcleritis from March 2021 to September 2021 were included. The mean time of onset of symptoms in patients with scleritis was 15.7 days (range, 4-30) and for episcleritis it was 13.2 days (range 2-30). Patients received COVISHIELD™ (10 patients) and COVAXIN™ (2 patients). Five patients had denovo inflammation and seven had recurrent inflammation. Episcleritis patients were treated with topical steroids and systemic COX2 inhibitors while patients with scleritis were treated with topical steroids/oral steroids/antiviral medications depending on the aetiology.
Conclusion: Scleritis and episcleritis following COVID-19 vaccination are milder and do not require intensive immunosuppression except in rare cases.
Keywords: COVAXINTM; COVID-19 vaccines; COVISHIELDTM; episcleritis; scleritis; topical steroids.